2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Carlton L. Schwab, MD

MD
Yale University School of Medicine
333 Cedar Street FMB 328
New Haven, CT
USA 06520

Papers:
140 Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, shows efficacy in the treatment of HER2 amplified carcinosarcoma in vitro and in vivo 262 Choice of adjuvant chemotherapy following neoadjuvant carboplatin/paclitaxel and delayed primary debulking 356 Neratinib, an irreversible pan-ErbB receptor inhibitor, is highly effective against primary cervical cancer cell lines harboring HER2/neu gene mutations 401 Mutations in the PIK3 pathway as a major determinant of trastuzumab resistance in uterine serous carcinoma